4.43+0.04 (+0.91%) At close: July 10 4:00PM EDT Day's Range 4.29 - 4.51 52 Week Range 2.75 - 6.60 Volume 90,218 Avg. Volume 128,127 time is coming up to see if that resistance around 4.50 will get break or not IMO worth to watch. specially if volume start moving ...it won't go very far without always you do your own DD +decision
didn't mean to start this thread ... how did I do it? I thought I posted on my scalping thread I better go back to bed at least here few news Jun-28-17 05:00PM VBI Vaccines Announces Results of Annual General and Special Meeting Marketwired Jun-26-17 08:30AM VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes Marketwired Jun-19-17 08:30AM VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac(TM) Marketwired -7.56% Jun-05-17 08:30AM VBI Vaccines to Present at Jefferies 2017 Global Healthcare Conference Marketwired May-02-17 08:30AM VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study Marketwired Apr-24-17 04:21PM 3 Different Companies, 3 Different Approaches to Tumors GuruFocus.com Apr-05-17 08:30AM VBI Vaccines to Present Updates on Multiple Programs at the World Vaccine Congress Marketwired 08:30AM VBI Vaccines to Present Updates on Multiple Programs at the World Vaccine Congress Apr-04-17 09:27AM The Market In 5 Minutes Benzinga 09:27AM The Market In 5 Minutes Apr-03-17 12:43PM What Dynavax Technologies Holders Need to Consider Heading Into the Heplisav-B PDUFA GuruFocus.com 12:43PM What Dynavax Technologies Holders Need to Consider Heading Into the Heplisav-B PDUFA
company profile 222 Third Street Suite 2241 Cambridge, MA 02142 United States 617-830-3031 http://www.vbivaccines.com Sector: Healthcare Industry: Biotechnology Full Time Employees: 88 VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. The company also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants. In addition, it is developing CMV vaccine program, which is in Phase I clinical trials for the prevention of human cytomegalovirus infection; and for glioblastoma multiforme, which is in preclinical testing stage. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS. More about VBI Vaccines Inc.
at least I am not going crazy I did deleted on the FIZZ thread.... moved into the scalping one no that is open we might as well leave it
as it got open I might as well keep updated (Torment0r gave me extra work ) 4.87+0.44 (+9.93%) At close: July 11 4:00PM EDT Day's Range 4.41 - 4.90 52 Week Range 2.75 - 6.60 Volume 190,239 Avg. Volume 127,850 A/H closed 4.95 +8 +1.64% after reaching 5.05 but only 8649 volume.... VBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac(TM) Hepatitis B Vaccine https://finance.yahoo.com/news/vbi-vaccines-announces-phase-3-200500826.html
